LKFT vs NBTX
Lakefront Biotherapeutics NV and Nanobiotix S.a., side by side — 8 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | LKFT | NBTX |
|---|---|---|
| Revenue | €1.1B | €32.6M |
| Net income | €320.9M | €-24.0M |
| Gross margin | 97.3% | · |
| Net margin | 28.9% | −73.5% |
| Return on equity | 10.5% | · |
| Diluted EPS | €4.87 | −€0.50 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | €-271.2M | €-34.0M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 20.15× | 1.09× |
| Revenue CAGR 5y | 18.4% | 67.0% |
| Profit CAGR 5y | · | · |
LKFT bills 34.1× the revenue of NBTX, and NBTX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
8 years side by side
| Fiscal year | LKFT | NBTX |
|---|---|---|
| FY2025 | €1.1B | €32.6M |
| FY2024 | €275.6M | €-7.2M |
| FY2023 | €239.7M | €36.2M |
| FY2022 | €241.2M | €4.8M |
| FY2021 | €234.4M | €2.6M |
| FY2020 | €478.1M | €2.5M |
| FY2019 | €834.9M | €2.5M |
| FY2018 | €278.7M | €3.5M |
Bottom line
| Fiscal year | LKFT | NBTX |
|---|---|---|
| FY2025 | €320.9M | €-24.0M |
| FY2024 | €74.1M | €-68.1M |
| FY2023 | €211.7M | €-39.7M |
| FY2022 | €-218.0M | €-57.0M |
| FY2021 | €-103.2M | €-47.1M |
| FY2020 | €-305.4M | €-33.6M |
| FY2019 | €149.8M | €-50.9M |
| FY2018 | €-29.3M | €-30.3M |
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +€1,079,655,000 | LKFT |
| FY2024 | +€282,840,000 | LKFT |
| FY2023 | +€203,517,000 | LKFT |
| FY2022 | +€236,473,000 | LKFT |
| FY2021 | +€231,737,000 | LKFT |
| FY2020 | +€475,541,000 | LKFT |
| FY2019 | +€832,360,000 | LKFT |
| FY2018 | +€275,187,000 | LKFT |
LKFT has reported the higher revenue in every one of these 8 fiscal years. The gap has widened since the earliest year compared.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
5 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +102.4 pp | LKFT |
| FY2023 | +198.0 pp | LKFT |
| FY2022 | +1103.1 pp | LKFT |
| FY2020 | +1273.3 pp | LKFT |
| FY2018 | +861.7 pp | LKFT |
LKFT has kept the higher net margin in every one of these 5 fiscal years.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBTX's net margin has been more volatile than LKFT's over the 5 comparable fiscal years — 532.7 percentage points of standard deviation against 64.1.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LKFT led in net margin in every one of the 5 comparable fiscal years — a structural lead, not a recent swing.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.